Pregnancy Outcomes: Effects of Metformin Study (POEM Study)

PHASE3RecruitingINTERVENTIONAL
Enrollment

500

Participants

Timeline

Start Date

November 26, 2019

Primary Completion Date

December 31, 2043

Study Completion Date

December 31, 2043

Conditions
Gestational DiabetesInsulin Resistance
Interventions
DRUG

Metformin TEVA 850 mg

At inclusion, patients (N=500) will be randomized 1:1 to metformin vs usual care (850 mg tablets, 3 times daily or, if tolerance is suboptimal, a lower maximally tolerated dose, 1-2 times daily), on top of diet and lifestyle, with an insulin rescue in both arms if needed.

Trial Locations (4)

Unknown

RECRUITING

Martini hospital Groningen, Groningen

RECRUITING

University Medical Center Groningen, Groningen

RECRUITING

Treant Zorggroep, Hoogenveen, Emmen, Stadskanaal

RECRUITING

Medical Center Leeuwarden, Leeuwarden

All Listed Sponsors
collaborator

Maastricht University Medical Center

OTHER

collaborator

University Medical Center Groningen

OTHER

collaborator

Frisius Medisch Centrum

OTHER

collaborator

Martini Hospital Groningen

OTHER

collaborator

Treant Zorggroep

UNKNOWN

collaborator

Nij Smellinghe Hosptial

OTHER

lead

Bethesda Diabetes Research Center

OTHER